|Bid||272.20 x 1100|
|Ask||273.28 x 3100|
|Day's Range||268.59 - 275.50|
|52 Week Range||114.41 - 275.50|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 07, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||237.90|
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, Ltd., (Nasdaq:BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient has been dosed in the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's investigational anti-Dickkopf-1 antibody (DKK1), DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, with or without chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ).
BeiGene presents Phase 3 data of tislelizumab in non-squamous non-small cell lung cancer and Phase 2 data of pamiparib in ovarian cancer at ESMO 2020.
BeiGene announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thurs, Sept 17, 2020 at 11:45am ET.